SARS-CoV-2 targets MAVS for immune evasion

A new study shows that the SARS-CoV-2 nucleocapsid protein represses the antiviral type I interferon response through direct interaction with the signalling adaptor protein MAVS. Targeting this process might be a useful therapeutic strategy to boost immunity against COVID-19.

Automated summary

A new study has shown that the SARS-CoV-2 nucleocapsid protein can suppress the antiviral response by directly interacting with the signalling adaptor protein MAVS. Targeting this pathway could be a promising therapeutic strategy to enhance immunity against COVID-19.